What's happening?

Demand for inhalation products with multiple APIs has surged in recent years as companies rise to the challenge of meeting the needs of respiratory patients worldwide.

To develop a successful combination drug product, it is crucial to choose the right manufacturing technique, which will depend on the dosage form you choose.

Different dosage forms have a varying impact on patient compliance and their ability to take medications effectively. Many patients struggle to consume standard tablet dosage forms due to various health problems, including dysphagia (a swallowing disorder) and Parkinson’s disease.

While oral solid dose (OSD) products may seem obsolete compared with the new generation of biopharmaceutical products, they remain extremely popular. 

The challenge for OSD products moving forward will be to maintain their advantage as other dosage forms such as parenteral products.

Europe’s reliance on active pharmaceutical ingredients (APIs) which are not manufactured domestically is now under the spotlight more than ever. Recent world events have led to several governments trying to influence companies to relocate their API and pharmaceutical production back to Europe, if not their home country.  

Asthma and chronic obstructive pulmonary disease (COPD) are some of the greatest challenges facing global health services, requiring a new generation of more effective treatments.

When it comes to treating pulmonary diseases, inhalation drugs are highly popular due to their ability to deliver the drug dose directly to where it is needed. However, they do pose challenges for drug developers when it comes to devising new products for the market.

This year, COVID-19 has demonstrated the importance of being prepared for the unexpected. No-one could have predicted an extended crisis like this, with society lockdowns, supply interruptions, and big challenges to overcome to continue business operations.

Patient adherence remains a major consideration for pharmaceutical manufacturers. Medication works effectively only when patients take the right amount at the right time in the right way.

Conceiving and developing a new drug from scratch can be one of the most satisfying experiences you can have. But it is challenging too – it’s by no means certain that your project will succeed and the more cutting-edge your technology, the higher the risk of failure. 

Drug development is an exciting field for any business to work in. However, it is not without its challenges, particularly for pharmaceutical start-ups embarking on developing their own newly discovered drug for the first time. 

The likelihood of failure is high for any drug development project, and the risk of this outcome grows the more revolutionary the product.